Kodiak Sciences, Inc. (KOD)
92.97
+1.62
(+1.77%)
USD |
NASDAQ |
Oct 20, 16:00
92.64
-0.33
(-0.35%)
After-Hours: 07:09
Kodiak Sciences Research and Development Expense (TTM) : 200.60M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 200.60M |
| March 31, 2026 | 187.28M |
| December 31, 2025 | 182.37M |
| September 30, 2025 | 168.65M |
| June 30, 2025 | 150.05M |
| March 31, 2025 | 139.81M |
| December 31, 2024 | 126.10M |
| September 30, 2024 | 140.95M |
| June 30, 2024 | 145.26M |
| March 31, 2024 | 179.71M |
| December 31, 2023 | 206.30M |
| September 30, 2023 | 215.66M |
| June 30, 2023 | 241.15M |
| March 31, 2023 | 247.93M |
| December 31, 2022 | 267.59M |
| September 30, 2022 | 287.19M |
| Date | Value |
|---|---|
| June 30, 2022 | 281.52M |
| March 31, 2022 | 253.18M |
| December 31, 2021 | 217.34M |
| September 30, 2021 | 179.10M |
| June 30, 2021 | 152.40M |
| March 31, 2021 | 127.56M |
| December 31, 2020 | 107.39M |
| September 30, 2020 | 82.86M |
| June 30, 2020 | 63.67M |
| March 31, 2020 | 51.95M |
| December 31, 2019 | 37.51M |
| September 30, 2019 | 31.53M |
| June 30, 2019 | 26.12M |
| March 31, 2019 | 20.92M |
| December 31, 2018 | 23.98M |
| September 30, 2018 | 20.28M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 5.748B |
| AbbVie, Inc. | 9.714B |
| Mirum Pharmaceuticals, Inc. | 282.06M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |